Spread through air spaces in lung adenocarcinoma with subsequent contralateral metachronous pulmonary lesion: a case report
This case report describes a patient with lung adenocarcinoma featuring spread through air spaces (STAS) visualized via cinematic rendering, who subsequently developed a metachronous contralateral lesion harboring a de novo EGFR T790M/L858R double mutation that was successfully managed with surgery and adjuvant almonertinib.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Lung cancer remains the leading cause of cancer-related death worldwide, with a specific type called adenocarcinoma being the most common form found in the lungs. For decades, doctors have relied on standard two-dimensional CT scans to spot tumors, but a newer understanding of how these cancers behave has changed the game. In 2015, the World Health Organization identified a specific way these tumors spread called "spread through air spaces." Instead of just growing as a solid lump, cancer cells can detach and float through the tiny air sacs inside the lung, landing nearby to form small, separate clusters. This behavior is dangerous because it increases the risk that the cancer will return after surgery, especially if only a small portion of the lung is removed. Doctors now know that seeing these tiny satellite clusters around a main tumor on a scan is a strong warning sign that the cancer is aggressive and requires more extensive surgery to clear out all the hidden cells.
A recent case report from researchers in China illustrates how modern imaging and careful observation can guide treatment for a patient with this specific type of lung cancer. The story begins with a 53-year-old woman who had no symptoms of illness but was found to have a 2.8-centimeter mass in her left lung during a routine medical checkup. Standard CT images showed the main tumor, but they also revealed several tiny, scattered nodules surrounding it. To get a better look at how these small spots related to the main mass and the surrounding lung tissue, the medical team used a sophisticated 3D imaging technique called cinematic rendering. This method creates photorealistic, lifelike images that allow doctors to see the depth and spatial arrangement of the tumor and its satellite nodules with much greater clarity than a flat scan. The images confirmed that the small nodules were indeed separate from the main tumor but clustered closely around it, a visual signature that strongly suggested the cancer was spreading through the air spaces.
Because of this finding, the surgeons decided to perform a lobectomy, which involves removing the entire lower lobe of the lung, rather than just a smaller wedge of tissue. This choice was made to ensure that any microscopic cancer cells floating in the air spaces near the tumor were removed along with the main mass. The surgery was successful, and pathology tests confirmed the diagnosis of invasive lung adenocarcinoma with the spread-through-air-spaces pattern. At that time, the cancer had not spread to the lymph nodes, so the patient did not receive chemotherapy or other drugs immediately after the operation. She was placed on a strict schedule of follow-up scans every six months to watch for any signs of the disease returning.
Eighteen months later, a new nodule appeared, but this time it was in the opposite lung, in the right middle lobe. This raised a difficult question: was this a new, separate cancer, or was it a recurrence of the original tumor that had traveled to the other side? The patient underwent a second surgery to remove this new growth. When the tissue was examined under a microscope, it was confirmed to be a second invasive lung adenocarcinoma, but it had a different mix of cell types and a higher grade of aggressiveness than the first tumor. Crucially, genetic testing of this second tumor revealed a specific double mutation in a gene called EGFR. One part of the mutation, known as L858R, is a common driver of lung cancer, while the other, T790M, is usually a sign that a cancer has become resistant to standard treatments. However, this patient had never taken any targeted cancer drugs before, meaning this T790M mutation was present from the start, a rare occurrence known as a de novo mutation.
Given the presence of this specific double mutation, the medical team prescribed a newer, third-generation targeted drug called almonertinib. This medication is designed to block the activity of both the common cancer-driving mutation and the T790M mutation simultaneously. The patient took the drug daily, and after twenty months of treatment, she remained free of any signs of cancer recurrence. The case highlights several important lessons for the medical community. It confirms that the tiny satellite nodules seen on CT scans are a reliable indicator of the spread-through-air-spaces pattern, helping surgeons decide how much lung tissue to remove. It also shows that advanced 3D imaging can make these hidden details visible, aiding in surgical planning. Finally, the discovery of a rare, pre-existing double mutation in a second tumor suggests that some patients may carry genetic traits that make them prone to developing multiple lung cancers, and it demonstrates that newer targeted drugs can be effective even when used after surgery to prevent the disease from coming back. While this is just one patient's story, it provides a clear example of how precise imaging, careful surgery, and tailored drug therapy can work together to manage complex lung cancer cases.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.